Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

Summary

This is a double blind, randomized, placebo-controlled, parallel design study in which 18 in participants with HIV (PWH) on suppressive antiretroviral therapy will be randomly assigned to receive vaccination with C62 followed by M4 (C62-M4), C62 and C1 followed by M4 and M3 (C1C62-M3M4), or placebo. The purpose of this study is to find out: * If it is safe for people to receive intramuscular (IM) vaccination with C62-M4 or C1C62-M3M4 * If giving participants these vaccine doses will improve their immune system response to help the body get rid of HIV in the cells

Timeline

Start

2022-10-13

Primary completion

2024-09-12

Completion

2025-01-10

Drugs

Indications